§ 356g. Standards for regenerative medicine and regenerative advanced therapies
562 words·~3 min read·
/usc/title-21/section-356gA research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)In general Not later than 2 years after December 13, 2016, the Secretary, in consultation with the National Institute of Standards and Technology and stakeholders (including regenerative medicine and advanced therapies manufacturers and clinical trial sponsors, contract manufacturers, academic institutions, practicing clinicians, regenerative medicine and advanced therapies industry organizations, and standard setting organizations), shall facilitate an effort to coordinate and prioritize the development of standards and consensus definition of terms, through a public process, to support, through regulatory predictability, the development, evaluation, and review of regenerative medicine therapies and regenerative advanced therapies, including with respect to the manufacturing processes and controls of such products.
(b)Activities
(1)In general In carrying out this section, the Secretary shall continue to—
(A)identify opportunities to help advance the development of regenerative medicine therapies and regenerative advanced therapies;
(B)identify opportunities for the development of laboratory regulatory science research and documentary standards that the Secretary determines would help support the development, evaluation, and review of regenerative medicine therapies and regenerative advanced therapies through regulatory predictability; and
(C)work with stakeholders, such as those described in subsection (a), as appropriate, in the development of such standards.
(2)Regulations and guidance Not later than 1 year after the development of standards as described in subsection (a), the Secretary shall review relevant regulations and guidance and, through a public process, update such regulations and guidance as the Secretary determines appropriate.
(c)Definitions For purposes of this section, the terms “regenerative medicine therapy” and “regenerative advanced therapy” have the meanings given such terms in section 356(g) of this title.
(June 25, 1938, ch. 675, § 506G, as added Pub. L. 114–255, div. A, title III, § 3036, Dec. 13, 2016, 130 Stat. 1104; amended Pub. L. 115–52, title IX, § 901(b), Aug. 18, 2017, 131 Stat. 1076.)
Connections17 cite this · traces to 3
Cited by 17 sections · top 15
public-private-law
statute-compilations
statutes-at-large
- Public Law 114–255To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes
- Public Law 115–52To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes
Traces to 3 documents
4 references not yet in our index
- June 25, 1938, ch. 675, § 506G
- 130 Stat. 1104
- 131 Stat. 1076
- 130 Stat. 1103
Citation graph
cites case law
§ 356g
Standards for regenerative medicine and regenerative advanced therapies
Bills×6
Pub. L.×3
Stat. Comp.×3
Stat.×3
Fed. Reg.×2
ActJune 25, 1938, ch. 675, § 506G
Stat.130 Stat. 1104
Stat.131 Stat. 1076
Stat.130 Stat. 1103
Cites 7Cited by 17 across 5 sources